@CharuAggarwalMD @PatelOncology @StephenVLiu @FDAOncology @OncoAlert @LudaBazhenovaMD @LeciaSequist @RamalingamMD @US_FDA @n8pennell Found this study from Brazil reporting #cost-effectiveness in the #advanced setting, although a full comparative analysis w
RT @econ_genomics: (3) Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequ…
(3) Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients | https://t.co/3RMkyd771n #healtheconomics